Omics disciplines such as metabolomics, lipidomics, and proteomics are essential tools in pharmaceutical and biotechnology research, supporting drug discovery, preclinical research, and translational R&D. By enabling deep molecular characterization of biological systems, omics technologies help research teams investigate disease mechanisms, identify therapeutic targets, and generate actionable insights during early-stage development.
In the pharmaceutical and biotech sectors, integrated omics services are widely applied across drug discovery and preclinical programs, from hypothesis generation and mechanism-of-action studies to biomarker discovery and validation. These data-driven approaches support informed decision-making throughout the research and early development phases of drug pipelines. In addition, preclinical pharmacokinetics (PK) studies play a key role in understanding the absorption, distribution, metabolism, and elimination (ADME) of candidate compounds during drug discovery.
At oloBion, we support preclinical ADME and DMPK studies through advanced bioanalytical workflows, helping research teams assess exposure, compound behavior, and biological response in non-clinical research settings. We also provide advanced multi-omics and preclinical PK services for pharmaceutical R&D, combining high-resolution analytical platforms with expert data interpretation. Our integrated workflows are designed to support research-focused projects, enabling scientific teams to accelerate discovery, reduce uncertainty in preclinical programs, and bridge fundamental research with real-world R&D challenges.
Lipid-related disease research: Identification of lipid profile changes associated with dyslipidemias, cardiovascular research models, neurodegenerative disease research contexts, and oncology research models to support the study of disease-associated biological mechanisms.
Lipid target discovery in drug research: Exploration of lipids and lipid-mediated pathways as potential targets to support drug discovery and early-stage research programs in pharmaceutical R&D.
Lipid biomarker research: Investigation of lipid-based molecular signatures to support research studies focused on efficacy, safety, and biological response in preclinical and translational research settings.
Cell membrane and lipid function research: Analysis of drug-induced effects on membrane structure and lipid organization to better understand compound–membrane interactions and lipid-driven cellular processes in research models.
Drug mechanism-of-action research: Identification of drug-affected metabolic pathways to support the understanding of compound mechanisms of action in drug discovery and preclinical research.
Biomarker discovery in pharmaceutical research: Identification of disease-associated metabolites to support research-focused biomarker discovery and mechanistic studies across pharmaceutical R&D programs.
ADME-related metabolomics studies: Analysis of metabolite profiles to support investigations related to absorption, distribution, metabolism, and elimination (ADME) in drug discovery and preclinical research contexts.
Pharmacometabolomics and response research: Investigation of metabolic variability in response to compounds to support research into exposure, biological response, and compound behavior during early-stage drug development.
Therapeutic target discovery research: Identification and characterization of disease-associated proteins to support target discovery and validation in pharmaceutical and biotechnology research programs.
Protein biomarker research: Detection and characterization of protein-level changes to support research studies focused on biological response, pathway analysis, and disease-associated mechanisms.
Biological modality and protein research: Analysis of protein targets and interactions to support research into advanced therapeutic modalities, including protein- and gene-based approaches, in early-stage and preclinical development.
Drug resistance and response research: Investigation of protein-level mechanisms associated with compound resistance and response in oncology, immunology/inflammation, and neuroscience research models, supporting drug discovery and preclinical research.
At oloBion, we provide cutting-edge omics services designed to empower researchers in the Pharmaceutical & Biotechnology industry. With our state-of-the-art technology and the expertise of our team, we help you unlock the full potential of your analytes (metabolites, lipids and proteins), driving discovery, innovation, and impactful solutions. Our portfolio includes both Untargeted and Targeted metabolomics, lipidomics and proteomics services, as well as ADME-DMPK assays, all tailored to meet the specific needs of your research.
Technique: LC-MS/MS
Untargeted lipidomics analysis for the identification of lipids by LC-MS/MS.The Identification includes a list with superclass, class, lipid name, and InChIKey.
Technique: LC-MS/MS
Untargeted lipidomics analysis for the identification of short chain fatty acids by LC-MS/MS. The indentification includes a list with superclass, class, lipid name, and InChIKey.
Technique: LC-MS/MS
Untargeted lipidomics analysis for the identification of lipids by LC-MS/MS, including oxylipins. The Identification includes a list with superclass, class, lipid name, and InChIKey.
Technique: LC-MS/MS
Untargeted lipidomics analysis for the identification of lipids by LC-MS/MS.The Identification includes a list with superclass, class, lipid name, and InChIKey.
Pharmacolipidomics analysis to identify key lipid classes and determine lipid biomarkers related to bioavailability, metabolism, and compound response, supporting ADME and mechanistic evaluation in preclinical studies.
Targeted lipidomics analysis for the quantification of total fatty acids (FW) (g/100g)
Technique: LC-MS/MS
Target Lipidomics analysis for the identification of specific lipid(s) according to customer requirements
Technique: LC-MS/MS
NextGen proteomics analysis by LC-MS/MS for the identification of proteins in plasma. The identification includes the family and name of the protein.
Technique: LC-MS/MS
NextGen proteomics analysis by LC-MS/MS for the identification of proteins in stool. The identification includes the family and name of the protein.
Technique: LC-MS/MS
NextGen proteomics analysis by LC-MS/MS for the identification of proteins. The identification includes the family and name of the protein.
Pharmacoproteomics analysis to identify key proteins and determine proteomic biomarkers related to drug metabolism, transport, and resistance mechanisms, supporting mechanistic insight in preclinical research.
Technique: LC-MS/MS
Target Proteomics analysis for the identification of specific protein(s) according to customer requirements
In vitro metabolic stability in liver microsomes, hepatocytes, and plasma, with metabolite profiling and reaction phenotyping to support ADME evaluation and compound selection in preclinical drug discovery.
Preclinical pharmacokinetics in rodents and non-rodents, including tissue distribution, renal excretion, and PK/PD studies to characterize exposure and support candidate progression.
Plasma, tissue, and red blood cell binding studies to determine unbound fraction and support exposure assessment, species comparison, and pharmacokinetic modeling in preclinical drug development.
Caco-2 permeability studies to assess compound absorption and P-gp/BCRP transporter interactions, supporting ADME characterization and compound prioritization in preclinical drug discovery.
In vitro CYP inhibition, time-dependent inhibition, induction, and P-gp/BCRP interaction studies to assess drug–drug interaction risk and support ADME evaluation in preclinical development.
Quantitative LC–MS/MS bioanalysis of compounds and biomarkers across plasma, serum, urine, blood, and tissues to support ADME, pharmacokinetics, and preclinical development.
Pharmacoproteomics analysis to identify key proteins and determine proteomic biomarkers related to drug metabolism, transport, and resistance mechanisms, supporting mechanistic insight in preclinical research.
Pharmacolipidomics analysis to identify key lipid classes and determine lipid biomarkers related to bioavailability, metabolism, and compound response, supporting ADME and mechanistic evaluation in preclinical studies.
Pharmacometabolomics studies to identify key metabolic pathways and determine metabolomic biomarkers associated with compound exposure and metabolic response, supporting ADME and mechanistic insight in preclinical research.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. The assays in this panel include proteins involved in key biological processes such as cellular regulation, development, signal transduction and stress responses.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Oncology II features putative cancer-related human proteins that participate in biological mechanisms that are central to the initiation and progression of cancer, e.g. angiogenesis, cell-cell signaling, cell-cycle control, and inflammation.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Organ Damage features biomarkers involved in biological response to organ damage with a main focus on stress response, but also on regulation of cell proliferation, the cell cycle, and cell death/apoptosis.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Oncology III includes biomarkers involved in angiogenesis, cell communication, cellular metabolic processes, apoptosis and cell proliferation/differentiation. It is a perfect complement to our Olink® Target 96 Oncology II panel.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Inflammation features the most extensive commercially available biomarker selection for proteins associated with inflammatory diseases such as arthritis, chronic obstructive pulmonary disease, diabetes, psoriasis, and related biological processes. It is compiled to detect a selection of both established and exploratory biomarkers within the inflammation research field.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Metabolism includes biomarkers involved in cellular metabolic processes, cell surface receptor signaling pathways, regulation of phosphorylation and cell adhesion.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. The Olink® Target 96 Immuno-Oncology panel covers biomarkers related to immunotherapy/checkpoint molecules and biomarkers involved in promotion and inhibition of tumor immunity, chemotaxis, vascular & tissue remodeling, apoptosis & cell killing, and metabolism & autophagy.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Immune Response includes biomarkers involved in key biological processes such as adaptive immune response, defense response to viruses, lymphocyte activation, inflammatory responses and cytokine-mediated signaling pathways.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Cardiovascular II focuses on cardiovascular and inflammatory biomarkers which have been carefully selected in collaboration with leading experts in the field. It also includes a selection of exploratory proteins with potential as new CVD markers.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Neuro Exploratory consists of a combination of exploratory and established biomarkers with a focus on neurology-related diseases, and biological processes such as axon development, neurogenesis and synapse assembly. This panel is a good complement to Olink® Target 96 Neurology.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. The Olink® Target 96 Development panel focuses on biomarkers involved in cell communication and developmental processes.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Cell Regulation includes biomarkers involved in key biological processes such as cell communication, apoptotic processes, the cell cycle and cell differentiation.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. The Olink® Target 96 Neurology features well-established biomarkers related to neurobiological processes and neurological diseases (e.g. neural development, axon guidance, synaptic function, or specific conditions such as Alzheimer’s disease). Also includes additional exploratory proteins with broader roles in processes such as cellular regulation, immunology, development and metabolism.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Cardiometabolic features biomarkers involved in cellular metabolic processes, cell adhesion, immune response and complement activation. It is an excellent complement to Olink® Target 96 Cardiovascular II and Olink® Target 96 Cardiovascular III.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. As well as the cardiovascular, CVD, and exploratory protein markers included in Cardiovascular II, the Olink® Target 96 Cardiovascular III panel concentrates on cell adhesion biomarkers, carefully selected in collaboration with leading cardiovascular scientists.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 43 specific proteins. Olink® Target 48 Mouse Cytokine panel is a high-performance solution for protein multiplex studies in the murine model. The thorough selection of targeted biomarkers allows for a comprehensive view of the murine immune response, in-depth disease modelling and longitudinal studies in mice.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 44 specific proteins. Olink® Target 48 Immune Surveillance panel is a high-performance solution for immune response and inflammation-related studies. The carefully selected range of biomarkers in this panel provides a great mean for studying key pathways related to cytokine signalling, inflammatory processes, and immune response in cancer.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 45 specific proteins. Olink® Target 48 Cytokine panel is the high-performance solution for cytokine studies and inflammation-related diseases, with absolute or relative quantification. The thorough selection of biomarkers ensures that the most important proteins covering key pathways related to cytokine signaling and inflammatory processes are well covered.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 5 to 30 specific protein(s) selected from a library of 197 proteins, according to customer requirements.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 21 specific proteins. A panel targeting biomarkers involved in biological pathways central for immuno-oncology research e.g., angiogenesis, growth regulation, apoptosis and immunity.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 21 specific proteins. Assays carefully selected for their scientifically proven importance in the uncontrolled inflammatory response condition commonly referred to as cytokine storm.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 26 specific proteins. Includes 26 biomarkers crucial for studying inflammation and providing deeper insights into the immune landscape.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 21 specific proteins. Curated based on UK Biobank proteomics data to include top biomarkers associated with type 2 diabetes.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 21 specific proteins. Aging is a multifaceted process characterized by systemic chronic inflammation. This carefully curated panel includes biomarkers crucial in age-related changes of the immune system.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 20 specific proteins. Interferon (IFN) inflammation is associated with immunotherapy resistance in melanoma. This panel is developed together with Dr. Mehta and is based on findings from the Nature Immunology paper “In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer” (Manguso et al.)
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 5 specific proteins. Combines 5 key proinflammatory markers for targeted studies of inflammation and immune response.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 21 specific proteins. This panel includes the most important cytokines characterizing the Th1/Th2/Th17 inflammatory profiles, thereby providing the ultimate solution for studies of the immune system.
Transform your omics data into actionable insights with oloMAP Portal, our interactive platform for advanced statistical analysis and visualization.
Combine multiple omics datasets to uncover relationships between biological layers, gain a holistic view of underlying processes and identify potential biomarkers.
Comprehensive biological interpretation from our experts to connect omics data with biological pathways, highlighting relevant mechanisms and potential biomarkers tailored to your study.
01
Contact and
Proposal
02
Send Samples
to the Lab
03
Sample Reception
and Processing
04
Mass Spectrometry
Analysis
05
Gain Insight into
oloMAP Portal
Standard Delivery Time:
6 weeks
Fast-track option available
Minimum Sample Amount:
Consult our experts for guidance
on sample requirements
Discount:
Associated with the number of
samples and multi-omics analysis
Partner with us to explore the power of omics in your field. Our team is ready to guide you through the process and deliver insights tailored to your research or industry needs.
Contact us today to discuss your project or schedule a consultation. Together, we’ll advance innovation through omics!